Trial Evaluating News Today

The positive results in both progression-free survival and overall response rate were endorsed in a confirmatory study.

PRINCETON, N.J.--(BUSINESS WIRE)--Mar 28, 2024--

  Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally...

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children...

27.02.2024 - GOTHENBURG, SWEDEN / ACCESSWIRE / February 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for ...

IRLAB to Present Clinical and Preclinical Data at the AD/PD(TM) 2024: ...

GOTHENBURG, SWEDEN / ACCESSWIRE / February 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will present two...

Data from the randomized phase 3 CABASTY trial “may be practice changing, especially in patients 65 years or older with mCRPC who are often denied chemotherapy in daily clinical routines,” investigators concluded. Lower-dose cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) lowers risks for older patients.

Compared to placebo, patients using once-daily oral HU6 100 mg, HU6 300 mg, and HU6 450 mg experienced significant changes in liver fat, volume, and whole-body adiposity after 61 days of treatment.

This new data results from the pivotal INTEGUMENT-PED trial and met both its primary and secondary endpoints.